ROS1 and non-small cell lung carcinoma: <h4>Objective</h4>To evaluate the cost-effectiveness by comparing four treatment strategies for ROS1-positive non-small cell lung cancer (NSCLC): first-line taletrectinib prior to chemotherapy, second-line taletrectinib following chemotherapy, second-line taletrectinib after crizotinib, and chemotherapy alone.<h4>Methods</h4>A partitioned survival model was constructed to analyze the clinical outcomes and healthcare expenditures associated with the four treatment strategies.